Date: 2005
Type: Thesis
The duty to deal in the biopharmaceutical industry : a follow-on innovation perspective
Florence : European University Institute, 2005, EUI, LAW, PhD Thesis
HARACOGLOU, Irina, The duty to deal in the biopharmaceutical industry : a follow-on innovation perspective, Florence : European University Institute, 2005, EUI, LAW, PhD Thesis - https://hdl.handle.net/1814/4653
Retrieved from Cadmus, EUI Research Repository
Using the example of research tools in biopharmaceutical research and innovation, this book examines the complexities of the relationship two fundamental areas of law and policy - intellectual property rights and competition law. It addresses a question that is certain to become paramount in other industries also: how to strike the balance between initial and follow-on innovation so as to ensure that access to 'essential' research tools (or other fundamental elements to follow-on innovation) is not impeded.The book concludes by suggesting how competition law could be used to complement the patent balance. "Competition Law and Patents" caters for various groups ranging from those with a general interest in competition law, patent law and/or biopharmaceuticals, to students who want to understand how competition and intellectual property work in practice (or to understand the interface between the two policies), and from practitioners and policymakers to people within the biopharmaceutical industry itself.
Additional information:
Defence date: 26 September 2005; Examining board: Prof. Hans Ullrich (Supervisor, European University Institute) ; Prof. Christian Joerges (Co-Supervisor, European University Institute) ; Prof. David Vaver (Oxford University) ; Prof. Bernand Remiche (Université Catholique de Louvain); PDF of thesis uploaded from the Library digitised archive of EUI PhD theses completed between 2013 and 2017
Cadmus permanent link: https://hdl.handle.net/1814/4653
Series/Number: EUI; LAW; PhD Thesis
Publisher: European University Institute
LC Subject Heading: Patent laws and legislation; Pharmaceutical biotechnology -- Patents; Pharmaceutical biotechnology -- Law and legislation; Competition, Unfair
Published version: http://hdl.handle.net/1814/23984